Cargando…

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandela, Irawati, Jin, Hyun Yong, Owen, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480271/
https://www.ncbi.nlm.nih.gov/pubmed/26111384
http://dx.doi.org/10.7554/eLife.07072
_version_ 1782378130848088064
author Kandela, Irawati
Jin, Hyun Yong
Owen, Katherine
author_facet Kandela, Irawati
Jin, Hyun Yong
Owen, Katherine
author_sort Kandela, Irawati
collection PubMed
description The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from ‘BET bromodomain inhibition as a therapeutic strategy to target c-Myc’ by Delmore and colleagues, published in Cell in 2011 (Delmore et al., 2011). The key experiments that will be replicated are those reported in Figures 3B and 7C-E. Delmore and colleagues demonstrated that treatment with JQ1, a small molecular inhibitor targeting BET bromodomains, resulted in the transcriptional down-regulation of the c-Myc oncogene in vitro (Figure 3B; Delmore et al., 2011). To assess the therapeutic efficacy of JQ1 in vivo, mice bearing multiple myeloma (MM) lesions were treated with JQ1 before evaluation for tumor burden and overall survival. JQ1 treatment significantly reduced disease burden and increased survival time (Figure 7C-E; Delmore et al., 2011). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife. DOI: http://dx.doi.org/10.7554/eLife.07072.001
format Online
Article
Text
id pubmed-4480271
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-44802712015-06-26 Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc Kandela, Irawati Jin, Hyun Yong Owen, Katherine eLife Human Biology and Medicine The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from ‘BET bromodomain inhibition as a therapeutic strategy to target c-Myc’ by Delmore and colleagues, published in Cell in 2011 (Delmore et al., 2011). The key experiments that will be replicated are those reported in Figures 3B and 7C-E. Delmore and colleagues demonstrated that treatment with JQ1, a small molecular inhibitor targeting BET bromodomains, resulted in the transcriptional down-regulation of the c-Myc oncogene in vitro (Figure 3B; Delmore et al., 2011). To assess the therapeutic efficacy of JQ1 in vivo, mice bearing multiple myeloma (MM) lesions were treated with JQ1 before evaluation for tumor burden and overall survival. JQ1 treatment significantly reduced disease burden and increased survival time (Figure 7C-E; Delmore et al., 2011). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife. DOI: http://dx.doi.org/10.7554/eLife.07072.001 eLife Sciences Publications, Ltd 2015-06-25 /pmc/articles/PMC4480271/ /pubmed/26111384 http://dx.doi.org/10.7554/eLife.07072 Text en © 2015, Kandela et al http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Human Biology and Medicine
Kandela, Irawati
Jin, Hyun Yong
Owen, Katherine
Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
title Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
title_full Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
title_fullStr Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
title_full_unstemmed Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
title_short Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
title_sort registered report: bet bromodomain inhibition as a therapeutic strategy to target c-myc
topic Human Biology and Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480271/
https://www.ncbi.nlm.nih.gov/pubmed/26111384
http://dx.doi.org/10.7554/eLife.07072
work_keys_str_mv AT kandelairawati registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc
AT jinhyunyong registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc
AT owenkatherine registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc
AT registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc